StreetInsider.com News Articles

Pasithea Therapeutics provides updated clinical trial timelines

Tue, 13 Jan 2026 07:03:48 +0000

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced updated timelines for its ongoing clinical trials of PAS-004, an oral macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 associated plexiform neurofibromas and advanced cancer patients.

The company has completed enrollment of 12 patients through the first four dose cohorts in Part A of its Phase 1/1b clinical trial in adult patients with NF1-PN. Pasithea plans to present data from this study in the second half of 2026, including efficacy data through the six-month timepoint for both plexiform and cutaneous neurofibromas, along with safety, tolerability and pharmacokinetic data.

For its Phase 1 clinical trial in

Pasithea Therapeutics provides updated clinical trial timelines

Tue, 13 Jan 2026 07:03:48 +0000

For its Phase 1 clinical trial in

Pasithea Therapeutics provides updated clinical trial timelines

Tue, 13 Jan 2026 07:03:48 +0000

For its Phase 1 clinical trial in

Pasithea Therapeutics provides updated clinical trial timelines

Tue, 13 Jan 2026 07:03:48 +0000

For its Phase 1 clinical trial in

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Tue, 13 Jan 2026 07:01:00 +0000

MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), today provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN patients.

Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):

Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets)

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Tue, 13 Jan 2026 07:01:00 +0000

Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):

Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets)

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Tue, 13 Jan 2026 07:01:00 +0000

Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):

Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets)

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Tue, 13 Jan 2026 07:01:00 +0000

Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):

Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets)

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Tue, 13 Jan 2026 07:01:00 +0000

Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):

Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets)

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Tue, 13 Jan 2026 07:01:00 +0000

Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):

Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets)

Pasithea advances PAS-004 trial to higher dose after safety review

Mon, 08 Sep 2025 07:01:12 +0000

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its external Safety Review Committee recommended proceeding to the second cohort of its Phase 1/1b clinical trial testing PAS-004 in adult patients with neurofibromatosis type 1.

The committee recommended escalating to an 8mg tablet dose level without modification after reviewing safety data from three patients in the first cohort. The review found no dose limiting toxicities, according to the company's statement.

Pasithea has enrolled the first three patients in the second cohort. Chief Executive Officer Dr. Tiago Reis Marques stated the company is experiencing substantial enrollment demand for the trial.

The Phase 1/1b study evaluates PAS-004,

Pasithea advances PAS-004 trial to higher dose after safety review

Mon, 08 Sep 2025 07:01:12 +0000

Pasithea has enrolled the first three patients in the second cohort. Chief Executive Officer Dr. Tiago Reis Marques stated the company is experiencing substantial enrollment demand for the trial.

The Phase 1/1b study evaluates PAS-004,

Pasithea advances PAS-004 trial to higher dose after safety review

Mon, 08 Sep 2025 07:01:12 +0000

Pasithea has enrolled the first three patients in the second cohort. Chief Executive Officer Dr. Tiago Reis Marques stated the company is experiencing substantial enrollment demand for the trial.

The Phase 1/1b study evaluates PAS-004,

Pasithea advances PAS-004 trial to higher dose after safety review

Mon, 08 Sep 2025 07:01:12 +0000

Pasithea has enrolled the first three patients in the second cohort. Chief Executive Officer Dr. Tiago Reis Marques stated the company is experiencing substantial enrollment demand for the trial.

The Phase 1/1b study evaluates PAS-004,

Pasithea advances PAS-004 trial to higher dose after safety review

Mon, 08 Sep 2025 07:01:12 +0000

Pasithea has enrolled the first three patients in the second cohort. Chief Executive Officer Dr. Tiago Reis Marques stated the company is experiencing substantial enrollment demand for the trial.

The Phase 1/1b study evaluates PAS-004,

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients